New potential standard-of-care for patients with CLDN18.2+/HER2- LA unresectable or mG/GEJ adenocarcinoma – an international perspective
In this MEDtalk, Dr. Wungki Park shares his perspective on the phase three results from the SPOTLIGHT study, which focuses on patients with CLDN18.2+/HER2- locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma and the treatment with zolbetuximab and mFOLFOX6 as first-line therapy.
